While MERTK expression has not been demonstrated in CLL, immunoblot analysis revealed a substantial increase in expression and activation of TYRO3 in B cells from patients with CLL compared to normal B cells [61]. This evidence concerns the gene TYRO3 and B-cell chronic lymphocytic leukemia.